Fourth, no mixing studies in a 1:1 proportion of tested samples with reference plasma were performed to rule out any potential coagulation factor deficiency since no correction of the dRVVT or aPTT-based assays in the presence of active FXa inhibitor molecules is expected as it was already proven by Merriman et al. (37). This evidence concerns the gene F10 and complement factor I deficiency.